Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study

• Published in: Journal of neuro-oncology Vol. 156; no. 3; pp. 625 - 634
• Main Authors: Moitra, Prithwijit, Chatterjee, Abhishek, Kota, Priti Khatri, Epari, Sridhar, Patil, Vijay, Dasgupta, Archya, Kowtal, Pradnya, Sarin, Rajiv, Gupta, Tejpal
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2022; Springer Nature B.V
• Subjects: Adult; Adults; Alleles; Biopsy; Blood cells; Brain Neoplasms - drug therapy; Brain Neoplasms - genetics; Clinical Study; Deoxyribonucleic acid; DNA; DNA methyltransferase; DNA Modification Methylases - genetics; DNA Repair Enzymes - genetics; Glioma; Glioma - drug therapy; Glioma - genetics; Humans; Medicine; Medicine & Public Health; Methylguanine; Myeloid Cells - drug effects; Myeloid Cells - pathology; Myelosuppression; Neurology; Neutropenia; O6-methylguanine-DNA methyltransferase; Oncology; Patients; Peripheral blood; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Single-nucleotide polymorphism; Statistical analysis; Temozolomide; Temozolomide - adverse effects; Thrombocytopenia; Toxicity; Tumor Suppressor Proteins - genetics; Myelotoxicity; Pharmacogenetic; Temozolomide; Glioma; MGMT; Polymorphism

Purpose Nearly 10% of patients with adult diffuse glioma develop clinically significant myelotoxicity while on temozolomide (TMZ) leading to treatment interruptions. This study aimed to assess single nucleotide polymorphisms (SNPs) in the O 6 -methylguanine-DNA methyltransferase ( MGMT ) gene in adu...